JP2004525855A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525855A5
JP2004525855A5 JP2001523012A JP2001523012A JP2004525855A5 JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5 JP 2001523012 A JP2001523012 A JP 2001523012A JP 2001523012 A JP2001523012 A JP 2001523012A JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5
Authority
JP
Japan
Prior art keywords
composition
sequence
protein
strain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001523012A
Other languages
English (en)
Japanese (ja)
Other versions
JP5060694B2 (ja
JP2004525855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/025510 external-priority patent/WO2001019380A2/en
Publication of JP2004525855A publication Critical patent/JP2004525855A/ja
Publication of JP2004525855A5 publication Critical patent/JP2004525855A5/ja
Application granted granted Critical
Publication of JP5060694B2 publication Critical patent/JP5060694B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001523012A 1999-09-17 2000-09-18 腫瘍崩壊性ウイルス Expired - Fee Related JP5060694B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
US09/397,873 1999-09-17
PCT/US2000/025510 WO2001019380A2 (en) 1999-09-17 2000-09-18 Oncolytic virus

Publications (3)

Publication Number Publication Date
JP2004525855A JP2004525855A (ja) 2004-08-26
JP2004525855A5 true JP2004525855A5 (enExample) 2007-11-15
JP5060694B2 JP5060694B2 (ja) 2012-10-31

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523012A Expired - Fee Related JP5060694B2 (ja) 1999-09-17 2000-09-18 腫瘍崩壊性ウイルス

Country Status (13)

Country Link
EP (2) EP1716858B9 (enExample)
JP (1) JP5060694B2 (enExample)
CN (1) CN1289098C (enExample)
AT (2) ATE418341T1 (enExample)
AU (1) AU782402B2 (enExample)
CA (1) CA2386920C (enExample)
DE (2) DE60041210D1 (enExample)
ES (2) ES2320239T3 (enExample)
HK (1) HK1044708B (enExample)
IL (2) IL148621A0 (enExample)
MX (1) MXPA02002772A (enExample)
NZ (4) NZ523805A (enExample)
WO (1) WO2001019380A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
WO2002000233A2 (en) 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
DE60239394D1 (de) 2001-05-11 2011-04-21 Wellstat Biologics Corp Onkolytische virustherapie
CA2452517A1 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
EP1606411B1 (en) * 2003-03-27 2008-12-10 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
WO2005117557A2 (en) 2004-06-01 2005-12-15 San Diego State University Foundation Expression system
US8236298B2 (en) 2004-08-20 2012-08-07 Viralytics Limited Methods and compositions for treatment of hematologic cancers
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
CN105769931B (zh) * 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2009082664A2 (en) * 2007-12-21 2009-07-02 Wyeth Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
WO2010020056A1 (en) 2008-08-21 2010-02-25 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
CA2755790A1 (en) 2009-03-16 2010-09-23 Mcmaster University Vaccination methods
EP2510088B1 (en) 2009-12-10 2016-10-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
CA2847413C (en) 2010-09-02 2018-05-22 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
US20140335117A1 (en) 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
HUE054698T2 (hu) * 2013-04-10 2021-09-28 Isd Immunotech Aps Immunszuppresszív domének gyógyszerként való felhasználása
CA2915045A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions and methods for enhancing virus replication
ES2566146T3 (es) * 2013-07-16 2016-04-11 Sia Latima Virus de ARN oncolítico genéticamente estable, método de fabricación y uso del mismo
CN107076727B (zh) * 2014-07-21 2019-11-01 诺威尔卢斯德克有限公司 用于确定患者特定突变的致癌指数的方法和系统
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
WO2018213412A1 (en) 2017-05-19 2018-11-22 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
SI3684786T1 (sl) * 2017-09-22 2025-03-31 Centre National De La Recherche Scientifique (Cnrs) Mutirani glikoprotein virusa vezikularnega stomatitisa
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
CN116724110A (zh) * 2020-08-14 2023-09-08 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
WO1993018790A1 (en) 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
AU731663B2 (en) * 1997-07-11 2001-04-05 Yale University Rhabdoviruses with reengineered coats
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
AP1968A (en) * 1997-12-22 2009-04-30 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein.
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
AU771110B2 (en) 1998-06-12 2004-03-11 Mount Sinai School Of Medicine Of The City University Of New York, The Novel methods and interferon deficient substrates for the propagation of viruses
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses

Similar Documents

Publication Publication Date Title
JP2004525855A5 (enExample)
IL148621A (en) Use of a virus for the manufacture of a medicament for reducing the viability of tumor cells and some isolated nucleic acid sequences
Ghaffari et al. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy
Fujioka et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection
Zhang et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
Shinozaki et al. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus
Cavalli et al. Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic
Nakamura et al. Oncolytic measles viruses for cancer therapy
JP2024531486A (ja) 環状ｒｎａを調製するための構築物及び方法
JP2004533449A5 (enExample)
ES2296750T3 (es) Forma mutada de la arginina deiminasa.
EP3740198A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
Prieto et al. Gene therapy of liver diseases
Fioravanti et al. Anchoring interferon alpha to apolipoprotein A‐I reduces hematological toxicity while enhancing immunostimulatory properties
EP1545627A4 (en) TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
WO2003092579A3 (en) Compositions and methods for treating cancer with an oncolytic viral agent
Wei et al. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors
JP2004532213A5 (enExample)
Lui et al. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo
Sato et al. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2
JP2005225888A5 (enExample)
Kim et al. Interferon alpha and beta receptor 1 knockout in human embryonic kidney 293 cells enhances the production efficiency of proteins or adenoviral vectors related to type I interferons
JP2007516214A5 (enExample)
JPWO2021243172A5 (enExample)
JP2008512399A5 (enExample)